Trulieve Cannabis stock (CA89788C1095): Profitable Q1 2026 on strong margins and cash flow

Trulieve Cannabis reported its first profitable quarter in 2026, posting net income of $2 million and $100 million in adjusted EBITDA on $287 million in revenue.

Trulieve Cannabis reported its first profitable quarter in 2026, posting net income of $2 million and $100 million in adjusted EBITDA on first?quarter revenue of $287 million, according to a May 7, 2026 press release from the company’s investor relations site.Trulieve investor relations as of 05/07/2026 The results mark a turnaround from recent quarters of losses and highlight improved gross margins of about 59%, which the company attributes to cost discipline and operational efficiencies across its vertically integrated cannabis platform.

As of: 10.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Trulieve Cannabis Corp.
• Sector/industry: Cannabis / Pharmaceuticals & Biotech
• Headquarters/country: Tallahassee, Florida, United States
• Core markets: U.S. medical and adult?use cannabis states
• Key revenue drivers: Dispensary retail, cultivation, branded products
• Home exchange/listing venue: Canadian Securities Exchange (TRUL), OTCQX (TCNNF)
• Trading currency: Canadian dollar (CSE), U.S. dollar (OTC)

Trulieve Cannabis: core business model

Trulieve Cannabis operates as a vertically integrated cannabis company that grows, processes, and sells medical and adult?use cannabis products across multiple U.S. states.Morningstar as of 05/10/2026 The company controls cultivation, manufacturing, and retail through its own facilities and branded dispensaries, which helps it capture value along the supply chain and maintain pricing power in fragmented state markets. Trulieve’s strategy focuses on high?margin branded products, including flower, concentrates, edibles, and topicals, sold through a large network of company?owned stores.

Trulieve’s footprint spans key cannabis states such as Florida, Arizona, and others, where it leverages scale and brand recognition to drive same?store sales growth.Perplexity Finance as of 05/10/2026 The company’s vertically integrated model allows it to manage product quality, supply reliability, and compliance with state?specific regulations, which is critical in a highly regulated and evolving U.S. cannabis environment. For U.S. investors, Trulieve offers exposure to the domestic cannabis market without direct federal legalization risk, since operations remain state?licensed and compliant.

Main revenue and product drivers for Trulieve Cannabis

Trulieve’s primary revenue driver is retail dispensary sales, supported by wholesale distribution of branded products to partner dispensaries in certain markets.Morningstar as of 05/10/2026 In the first quarter of 2026, the company generated $287 million in revenue, with gross margins of about 59%, reflecting strong pricing and efficient cultivation and production operations. Over the trailing 12 months through the fourth quarter of 2025, Trulieve reported roughly $1.18 billion in revenue and a net loss of about $110.8 million, indicating that the business has been scaling but still faces profitability headwinds.Simply Wall St as of 05/10/2026

Within the product mix, higher?margin concentrates and edibles have become increasingly important contributors to revenue and profitability.StockAnalysis as of 05/10/2026 Trulieve’s branded portfolio includes proprietary flower strains and infused products that command premium pricing compared with generic or private?label offerings. The company also benefits from economies of scale in cultivation and distribution, which help offset regulatory and compliance costs. For U.S. investors, this product mix and scale position Trulieve as a potential consolidator in a fragmented cannabis sector, though execution risk and regulatory uncertainty remain material.

Why Trulieve Cannabis matters for U.S. investors

Trulieve Cannabis matters for U.S. investors because it provides direct exposure to the U.S. cannabis market through a large, state?licensed retail and cultivation platform.Perplexity Finance as of 05/10/2026 The company operates one of the largest dispensary networks in the country, with more than 200 branded locations across key states, giving it significant consumer reach and brand visibility. As U.S. cannabis policy continues to evolve, including the recent reclassification of medical marijuana to Schedule III under the Controlled Substances Act, Trulieve stands to benefit from improved banking access, reduced tax burdens, and potential federal regulatory clarity.PR Newswire as of 05/07/2026

For U.S. retail investors, Trulieve offers a way to participate in the growth of legal cannabis without investing in smaller, less?established operators.Morningstar as of 05/10/2026 The company’s scale, brand strength, and vertical integration can provide competitive advantages in pricing, product quality, and regulatory compliance. However, investors should also consider the risks associated with state?by?state regulation, potential federal policy shifts, and ongoing profitability challenges, which can create volatility in the stock.

Conclusion

Trulieve Cannabis delivered its first profitable quarter in 2026, reporting net income of $2 million and $100 million in adjusted EBITDA on $287 million in revenue, signaling progress toward sustainable profitability.Trulieve investor relations as of 05/07/2026 The company’s vertically integrated model, strong gross margins, and large dispensary network position it as a leading player in the U.S. cannabis market, with meaningful exposure to both medical and adult?use consumers. For U.S. investors, Trulieve offers a way to access the sector’s growth potential, but the stock remains sensitive to regulatory developments, competitive dynamics, and execution risk.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.